Source-grounded facts extracted from BriaCell Therapeutics Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BriaCell Therapeutics Corp. entered into Placement Agency Agreement with ThinkEquity LLC valued at $4.71 million (effective 2026-05-31).
“On May 31, 2026, BriaCell Therapeutics Corp. (the “Company”) entered into a Placement Agency Agreement (the “Agreement”) with ThinkEquity LLC”
BriaCell Therapeutics Corp. entered into Warrant Agent Agreement with Computershare Inc. and Computershare Trust Company, N.A. (effective 2026-01-15).
“On January 15, 2026, the Company also entered into a Warrant Agent Agreement (the “Warrant Agent Agreement”) with Computershare Inc. and Computershare Trust Company, N.A. (“Computershare”), pursuant to which Computershare agreed to act as transfer agent with respect to the Warrants.”
BriaCell Therapeutics Corp. entered into Placement Agency Agreement with ThinkEquity LLC valued at $30 million (effective 2026-01-13).
“On January 13, 2026, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with ThinkEquity LLC (the “Placement Agent”), pursuant to which the Company agreed to issue and sell directly to investors, in a best efforts basis the Common Units and the Pre-funded Units.”
Marc Lustig resigned as director at BriaCell Therapeutics Corp..
“On November 23, 2024, Marc Lustig resigned from the board of directors of BriaCell Therapeutics Corp. (the “Company”)”
BriaCell Therapeutics Corp. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Cash fee of 7.0% of gross proceeds; Placement Agent Warrants for 50,000 shares at $2.321 per share (effective 2024-05-14).
“In connection with the Offering, on May 14, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”).”
BriaCell Therapeutics Corp. entered into Securities Purchase Agreements with certain investors valued at Gross proceeds of $5,000,000 from sale of shares and warrants (effective 2024-05-14).
“On May 14, 2024, BriaCell Therapeutics Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain investors (collectively the “Purchasers”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.